Arcellx Inc. (ACLX)
| Bid | 63.51 |
| Market Cap | 3.5B |
| Revenue (ttm) | 107.94M |
| Net Income (ttm) | -107.35M |
| EPS (ttm) | -2 |
| PE Ratio (ttm) | -31.79 |
| Forward PE | -26.24 |
| Analyst | Buy |
| Ask | 63.66 |
| Volume | 93,945 |
| Avg. Volume (20D) | 647,526 |
| Open | 63.82 |
| Previous Close | 63.71 |
| Day's Range | 63.55 - 65.78 |
| 52-Week Range | 47.88 - 107.37 |
| Beta | 0.33 |
About ACLX
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent Sp...
Analyst Forecast
According to 12 analyst ratings, the average rating for ACLX stock is "Buy." The 12-month stock price forecast is $114, which is an increase of 79.30% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
2 months ago · businesswire.com
Arcellx to Participate at the TD Cowen 45th Annual Health Care ConferenceREDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and...